Adenovirus-IL-10 relieves chronic rejection after mouse heart transplantation by inhibiting miR-155 and activating SOCS5

Gangcheng Kong, Yuqi Chen, Zongtao Liu, Yixuan Wang, Huadong Li, Chao GuoInternational Journal of Medical Sciences 2023 · DOI

Abstract

Chronic rejection is a primary barrier to the long-term survival of heart transplant recipients. This study investigates the therapeutic potential of Interleukin-10 (IL-10) in a mouse model of chronic rejection, focusing on its role in macrophage polarization. Researchers established a mouse heart transplant model and used an adenovirus vector (ad-IL-10) to overexpress IL-10. Results demonstrated that IL-10 levels naturally decline during chronic rejection. Treatment with ad-IL-10 significantly reduced pathological injury, perivascular fibrosis, and inflammation. Mechanistically, IL-10 was found to downregulate miR-155, which in turn activated SOCS5, promoting a shift from pro-inflammatory M1 macrophages to pro-repair M2 macrophages. These findings suggest that the IL-10/miR-155/SOCS5 axis is a promising target for mitigating chronic allograft rejection.

The Challenge of Chronic Rejection

While acute rejection after heart transplantation is often manageable with modern immunosuppressants, chronic rejection remains a persistent threat. It is characterized by progressive vascular stenosis—the narrowing of blood vessels—and interstitial fibrosis, which eventually leads to graft failure.

EVG staining showing progressive vascular narrowing and intimal hyperplasia in the mouse heart transplant model over 8 weeks.

Central to this process are macrophages, immune cells that can adopt different functional states. Pro-inflammatory M1 macrophages exacerbate tissue damage, while M2 macrophages promote healing and immune tolerance. Understanding how to shift this balance is key to preventing chronic rejection.

IL-10: A Natural Defense Overwhelmed

Interleukin-10 (IL-10) is a well-known anti-inflammatory cytokine, but its specific regulatory role in transplant-related macrophage behavior was previously unclear. This study found that in the heart tissues of mice experiencing chronic rejection, IL-10 expression significantly decreases over time.

Relative expression of IL-10 mRNA in heart tissue significantly decreases over time in the chronic rejection model compared to sham controls.

This natural decline suggests that the body's inherent regulatory mechanisms are insufficient to counteract the chronic immune response, providing a rationale for supplemental IL-10 therapy.

The miR-155/SOCS5 Signaling Pathway

The researchers identified a specific molecular "switch" controlled by IL-10. They discovered that IL-10 negatively regulates the microRNA miR-155. Under normal rejection conditions, high levels of miR-155 suppress the protein SOCS5, which is necessary for M2 macrophage polarization. By delivering IL-10 via an adenovirus vector (ad-IL-10), the researchers were able to inhibit miR-155, thereby activating SOCS5.

This activation successfully "reprogrammed" the immune environment:

  • Phenotypic Shift: There was a marked increase in M2 macrophages (Arg-1+, CD206+) and a decrease in M1 macrophages (iNOS+, CD16/32+).
  • Regulatory T-cells: The treatment also increased the proportion of TIGIT+ regulatory T-cells (Tregs), further promoting immune tolerance.

Conclusion and Future Directions

By targeting the IL-10/miR-155/SOCS5 axis, researchers successfully mitigated the pathological hallmarks of chronic rejection in mice. While these results are promising, translating them to human patients will require overcoming challenges in gene delivery specificity and understanding the complex interactions between various immune cell types in the human transplant environment.

Summary updated

Abstract

<b>Objective:</b> Chronic rejection remains the main factor that influence long-term survival of patients after heart transplantation. Interleukin-10 (IL-10) play critical role in macrophages-mediated transplant immune responses. We investigated the mechanism of IL-10 in macrophage related chronic rejection after mouse heart transplantation. <b>Methods:</b> Mouse heart transplant chronic rejection model was established to evaluate pathological changes in the allograft. Myocardial interstitial fibrosis, apoptosis, and inflammatory factor levels were detected in ad-IL-10-treated mice. The positive iNOS<sup>+</sup> and Arg-1<sup>+</sup> expressions, macrophage subset changes, and the proportion of regulatory T-cells (Tregs) and TIGIT<sup>+</sup> Tregs were quantified by flow. In in vitro experiments, ad-IL-10 was transfected into macrophages followed by detection of apoptosis, phagocytosis, and CD163, CD16/32, and CD206 expression. The expression and relationships between IL-10, miR-155, and SOCS5 were also detected and verified. A rescue experiment was performed to evaluate macrophage function through the combined treatment of ad-IL-10 and overexpression of miR-155. <b>Results:</b> Significantly decreased IL-10 expression in chronic rejection during mouse heart transplantation was observed. Ad-IL-10-treated mice showed decreased pathological injury, perivascular fibrosis, apoptosis, inflammation, and iNOS<sup>+</sup> and CD16/32<sup>+</sup> expression, and increased Treg/TIGIT<sup>+</sup> Treg cell, Arg-1<sup>+</sup> and CD206<sup>+</sup> cell proportion. Ad-IL-10-treated macrophages in vitro showed reduced apoptosis, improved phagocytosis, and M2 polarization. Mechanically, IL-10 negatively regulated miR-155 to activate SOCS5. Overexpression of miR-155 reversed IL-10 mediated-positive regulation of macrophage function. <b>Conclusion:</b> IL-10 downregulated miR-155 and activated SOCS5, thereby promoting macrophage M2 polarization to relieve chronic rejection after heart transplantation.
BibTeX
@article{kong2023adenovirus,
  author = {Gangcheng Kong and Yuqi Chen and Zongtao Liu and Yixuan Wang and Huadong Li and Chao Guo},
  title = {{Adenovirus-IL-10 relieves chronic rejection after mouse heart transplantation by inhibiting miR-155 and activating SOCS5}},
  journal = {International Journal of Medical Sciences},
  year = {2023},
  doi = {10.7150/ijms.77093},
}
Figure